Press Releases

17/12/2018 OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer

10/12/2018 OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage OSE-127

26/11/2018 OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate OSE-127

20/11/2018 OSE Immunotherapeutics and GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Pancreatic cancer

02/11/2018 OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104

30/10/2018 OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies

29/10/2018 OSE Immunotherapeutics Announces Publication in Nature Communications on OSE-127

10/10/2018 OSE Immunotherapeutics and GERCOR Announce Submission of a Clinical Trial Application for Tedopi®

01/10/2018 OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum

11/09/2018 OSE Immunotherapeutics Announces Issuance of a European Patent Protecting FR104

06/09/2018 OSE Immunotherapeutics Reports First-Half 2018 Results

22/08/2018 OSE Immunotherapeutics Publishes New Efficacy Data on FR104

05/07/2018 OSE Immunotherapeutics Receives a €435,000 Translational Research Grant

02/07/2018 OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

13/06/2018 OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting

17/05/2018 OSE Immunotherapeutics to Present at 4th Annual Immuno-Oncology: BD&L and Investment Forum

07/05/2018 OSE Immunotherapeutics Presents New Data on OSE-127

23/04/2018 OSE Immunotherapeutics Receives the Euronext Tech40 Label

1 2 3 4 5 6 7 8 9 10 11 12 13 14